<DOC>
	<DOCNO>NCT02340858</DOCNO>
	<brief_summary>This trial study well Irreversible Electroportion ( IRE ) therapy work treat patient breast cancer . IRE kill tumor cell Electrical impulse create nano-pore cell membrane induce target cell death.This may effective treatment patient unresectable breast cancer .</brief_summary>
	<brief_title>Percutaneous Irreversible Electroportion Unresectable Breast Cancer</brief_title>
	<detailed_description>This phase I/II non-randomized exploratory study . All fully eligible registered patient undergo image mammography , ultrasound , breast MRI . The primary secondary objective study describe . OBJECTIVES Primary Treatment efficacy measure modify Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Computed Tomography ( CT ) Magnetic Resonance ( MR ) imaging . secondary Safety use Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 criterion . To describe adverse event associate IRE To prospectively gather pain assessment data cryoablation surgical resection Explore technical variable may affect success IRE</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women 18 year older unresectable breast cancer , amenable/willing adenomammectomy . 2. breast carcinoma diagnose core needle biopsy . 3 . Any menopausal status . 4 . No history en bloc open surgical biopsy and/or lumpectomy diagnostic/treatment index breast cancer . 5 . Tumor size â‰¤ 5.0 cm great diameter . Largest size measure require scan ( mammogram , ultrasound MRI ) use determine eligibility . 6 . Tumor enhancement prestudy MRI . 7 . Tumor &lt; 25 % intraductal component aggregate . 8 . Progressed within 12 month prior adjuvant progress within 1 month prior advanced/metastatic endocrine breast cancer therapy , 9 . Nonpregnant nonlactating . Patients childbearing potential must negative serum urine pregnancy test . 10 . Adequate breast size safe IRE . Male breast cancer patient female breast cancer patient breast small allow safe IRE eligible minimal thickness breast tissue lend IRE . NOTE : For patient breast implant , treat physician must document adequate distance exist lesion implant ensure ablated lesion contact jeopardize implant . 11 . Adequate organ marrow function , resolution toxic effect prior therapy surgical procedure 12 . Patient must agree provide tumor tissue metastatic tissue baseline . 1 . Patients multifocal and/or multicentric ipsilateral breast cancer , multifocal calcification , evidence excessive DCIS . 2 . History rotational vacuum assist core biopsy , en bloc open surgical biopsy and/or lumpectomy diagnosis/treatment index breast cancer . 3 . Prior plan neoadjuvant chemotherapy breast cancer . 4 . Patients thrombocytopenia coagulation abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>